Laddar...
The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia
Antibody–drug conjugates (ADCs) are likely to make a significant contribution in the treatment of acute lymphoblastic leukemia (ALL) by combining the cytotoxicity of chemotherapy with the specificity of monoclonal antibodies. CD22, an endocytic receptor expressed by the majority of B cells, is an ex...
Sparad:
| I publikationen: | Ther Adv Hematol |
|---|---|
| Huvudupphovsmän: | , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
SAGE Publications
2015
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4556970/ https://ncbi.nlm.nih.gov/pubmed/26425338 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620715596715 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|